Sentences with phrase «cell therapy strategy»

In countries with socialized healthcare, governments have a strong interest in obtaining access to low - cost and effective long - term remedies, and may prove willing to invest in research and development if the economics of the cell therapy strategy are shown to be attractive.

Although the gene / cell therapy strategy was highly successful in laboratory mice, the authors stressed that additional research and testing are needed before the therapy could be tested in humans.

Overall, SR - Tiget represents a multi-disciplinary research environment, which provides a unique blend of scientific expertise in the development of innovative gene and cell therapy strategies, access to relevant preclinical models to evaluate their efficacy and safety, as well as competence in conducting early phase clinical trials.

Not exact matches

Disney said the precise binding of Targapremir - 18a to microRNA - 18a means a cancer drug that follows this strategy would be likely to kill prostate cancer cells without causing the broader side effects seen with many other cancer therapies.

The Wyss team believes the ability of the human gut - on - a-chip to culture the microbiome with human gut cells also holds promise for the field of precision medicine, where a patient's own cells and gut microbiota could one day be cultured inside a gut - on - a-chip for testing different therapies and identifying an individualized treatment strategy.

Now a University of Colorado Cancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining this failure and offering a possible strategy for the use of retinoic acid or other retinoids against some breast cancers: Because early clinical trials are often offered to patients who have already tried other more established therapies, breast cancer cells may have been pushed past an important tipping point that offers retinoic acid resistance.

This has motivated novel cardiotherapeutic strategies to repair and regenerate heart muscle, including human mesenchymal stem cell (hMSC) therapy.

By combining this strategy with cancer cell - targeting materials, we should be able to develop a therapy for glioblastoma and other challenging cancers in the future.»

Restoring normal function to a mutated protein is more difficult than simply blocking a protein, the strategy used by most medical therapies, says Klas Wiman, a tumor cell biologist at the Karolinska Institute in Stockholm.

If further research confirms the findings in human cells, limiting the amount of asparagine cancer patients ingest could be a potential strategy to augment existing therapies and to prevent the spread of breast cancer, Knott added.

Another strategy, which Steinman and others were studying, involves a therapy to target dendritic cells inside the body rather than taking them out and personalizing therapy for each patient.

Muscle biologists Qi Long Lu and Terence Partridge at the Medical Research Council Clinical Sciences Centre in London, U.K., and their colleagues decided to combined the antisense strategy with a chemical often used in gene therapy because it is known to improve delivery of DNA into cells.

To strengthen its clinical research profile, Dresden has created a strategic plan, to be funded by the German Research Ministry (BMBF), that focuses on three aspects of clinical research: tissue engineering and development of physical and molecular medical technologies for clinical application; therapeutic strategies after cell and tissue damage; and diagnosis and therapy of malignant diseases.

«The concept of exosome therapy is interesting because it could potentially shift our strategy from living - cell transplantation to the use of a non-living agent,» he added.

Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)- infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection.

Inhibitory control Other strategies being pursued to prevent the formation of inhibitors of clotting - factor therapy include immunosuppressants and drugs that deplete specific immune cells.

Hematopoietic stem cell transplantation (HSCT), once considered an effective yet risky alternative to drug therapy for blood cancer, has become more accessible and successful in a wide range of patients as a result of major advances in transplant strategies and technologies.

And, in fact, these doctors and researchers are finding incredible success with this strategy; for example, PD - 1 inhibitors remove this «cloak» that cancers use to hide from the immune system, and CAR - T cell therapies use specially engineered T - cells to seek cancer - specific proteins and destroy the cancer cells to which they are attached.

«We found that the NFkB - Pim1 - Eomes axis, an important molecular mechanism that operates in memory T cells, could be enhanced with molecular or genetic strategies to help current vaccines or tumor therapies be more effective.

Ideally, therapy for autoimmune diseases should eliminate pathogenic autoimmune cells while sparing protective immunity, but feasible strategies for such an approach have been elusive.

The basic CAR T cell concept was first described in the late 1980s, principally as an anti-cancer strategy, but technical challenges delayed its translation into successful therapies.

«In turn, we will be able to develop new and safer cell - therapy strategies.»

«These findings suggest that BES may thus be used as a strategy to improve cell survival and prevent cell apoptosis in stem cell - based transplantation therapies,» Fan explained.

The authors noted: «From this perspective, by strengthening tumor - associated immune responses, targeting [regulatory T cell] autophagy could act in synergy with strategies that block autophagy in tumor cells for added benefits in cancer therapy.»

The study published online in the journal Brain also describes a strategy of preventing the potential negative consequences of stem cell therapy.

Taken together, these observation impinge on one central problem: the development of rational targeting strategies aimed at overcoming therapeutic resistance require the precise elucidation of the molecular mechanisms whereby carcinoma cells that undergo EMT acquire the functional traits that render them resistant to conventional therapy.

The strategy developed by research teams and development of I - Stem aims to identify innovative therapies applicable to rare genetic diseases based on exploring the potential offered by human pluripotent stem cells.

Therapeutic strategies aiming at restoring the function of the implicated genes (gene and cell therapies) are very encouraging but not applicable in a near future to the variety of MDs.

Unraveling these mechanisms leads to new concepts and strategies for clinical intervention, including disease modeling, drug screening, and cell therapy.

While pluripotent stem cell - based therapies are an exciting option, this approach has several barriers to its application, although Iqbal Ahmad (University of Nebraska Medical Center, USA) has now proposed the use of a «non ‐ cell autonomous» reprogramming strategy as a new and improved therapeutic approach [2].

Future therapies will have to be based on strategies that act by reducing or increasing the number or activity of specific subtypes of pre - and postsynaptic receptors, transporters, and ion channels, or other membrane molecules at the synapse, and by strategies that exploit the new possibilities offered by stem cell technology and targeted repair.

The program covers six plenary sessions, six workshops, three technical sessions, and more than 20 total track sessions covering such topics as advances in cell therapy research, commercialization strategies, quality and operations, and regulatory issues.

The ability of cells to remain unaffected by HIV, in the absence of CCR5, has already been shown clinically, but this strategy has not been joined with gene therapy in making killer cells.

Format: Website Years Covered: currently active UK trials as of June 2017 Search Strategy: Not disclosed Project Focus: advanced cell therapy, active that year, in the UK only Special Notes: on - line sort by 4 parameters, archives for previous years back to 2012.

Format: Website Years Covered: Cumulative to 31 October 2017 Search Strategy: Manually search a dozen registries by keywords Project Focus: On - line search portal of all currently recruiting cord blood trials, both advanced cell therapy and standard hematology / oncology, worldwide

Panelists will discuss how scientists are investigating what happens to these cells as we age, how this knowledge is being used to guide new strategies to boost brain health and to develop therapies utilizing stem cells to treat diseases of the brain.

The third Objective (IRF3) brings together promising scientists and clinicians from the University of Pennsylvania and the Rockefeller University to combine gene therapy strategies, independently tested in humans, with the goal of engineering, growing, and administering killer cells that are uniquely empowered to find and kill HIV - infected cells.

Format: Publication Years Covered: Feb 2000 - June 2010 Search Strategy: Manually search registry by keywords Project Focus: Decadal review ClinicalTrials.gov Special Notes: Found 2724 cell therapy trials total, eliminate 37 % (1008) that are «conventional grafts»

Format: Publication Years Covered: 1992 - 2012 Search Strategy: Manually search registries by keywords Project Focus: Two Decades review of the world Special Notes: Found 4749 cell therapy trials total, but only 1058 are «novel» therapy

Format: Website Years Covered: Jan. 2011 - Dec. 2017 Search Strategy: Manually search a dozen registries by keywords Project Focus: any trials of advanced cell therapy, worldwide

Where treatment strategies have been exhausted, no - option patients may find hope for improvement of their condition with cardiac stem cell therapy for angina.

We believe Paul's leadership and business development skills will greatly assist us in our strategy to be a leader in regenerative medicine therapy and to capitalize on our current technology leadership position in the development of stem cell therapy.»

His efforts seek to define how tumor cells escape dormancy for growth, invasion, and metastasis, and how to best develop strategies for therapy.

Stem cell ‐ based therapies under investigation as a strategy for the treatment of Type 1 diabetes mellitus (T1DM) include the differentiation of cells towards engineered β cells [1] and the use of mesenchymal stem cells (MSCs) in the prevention or reversal of autoimmune and chemical ‐ induced diabetes [2].

Cassian Yee, M.D. University of Washington Fred Hutchinson Cancer Research Center Adoptive therapy of cancer: strategies to augment the antigen - specific T cell response

Acknowledgments We express sincere thanks to the following organizations that have contributed to the CASMI Translational Stem Cell Consortium (CTSCC) as funding and events partners, without whom the consortium and the benefits it will bring to stem cell translation would be constrained: GE Healthcare, the Center for Commercialization of Regenerative Medicine (CCRM), Sartorius Stedim Biotech (formerly TAP Biosystems), Lonza, the California Institute for Regenerative Medicine (CIRM), the Strategies for Engineered Negligible Senescence (SENS) Research Foundation, UK Cell Therapy Catapult, NIH Centre for Regenerative Medicine, the New York Stem Cell Foundation (NYSCF), ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche and Oxford BiomedCell Consortium (CTSCC) as funding and events partners, without whom the consortium and the benefits it will bring to stem cell translation would be constrained: GE Healthcare, the Center for Commercialization of Regenerative Medicine (CCRM), Sartorius Stedim Biotech (formerly TAP Biosystems), Lonza, the California Institute for Regenerative Medicine (CIRM), the Strategies for Engineered Negligible Senescence (SENS) Research Foundation, UK Cell Therapy Catapult, NIH Centre for Regenerative Medicine, the New York Stem Cell Foundation (NYSCF), ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche and Oxford Biomedcell translation would be constrained: GE Healthcare, the Center for Commercialization of Regenerative Medicine (CCRM), Sartorius Stedim Biotech (formerly TAP Biosystems), Lonza, the California Institute for Regenerative Medicine (CIRM), the Strategies for Engineered Negligible Senescence (SENS) Research Foundation, UK Cell Therapy Catapult, NIH Centre for Regenerative Medicine, the New York Stem Cell Foundation (NYSCF), ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche and Oxford BiomedCell Therapy Catapult, NIH Centre for Regenerative Medicine, the New York Stem Cell Foundation (NYSCF), ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche and Oxford BiomedCell Foundation (NYSCF), ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche and Oxford Biomedica.

Finally, the strategy described here may be a valuable tool for creating safer patient - specific cells and thus could have major implications for future cell therapy.

This work, published in «Blood», was carried out by the CNIO Telomeres and Telomerase Group The treatment is based on the transport of the telomerase gene to the bone marrow cells using gene therapy, a completely new strategy in the treatment of aplastic anaemia

Acknowledgments We express sincere thanks to the following organizations that have contributed to the CASMI Translational Stem Cell Consortium (CTSCC) as funding and events partners, without whom the consortium and the benefits it will bring to stem cell translation would be constrained: GE Healthcare, the Center for Commercialization of Regenerative Medicine (CCRM), Sartorius Stedim Biotech (formerly TAP Biosystems), Lonza, the California Institute for Regenerative Medicine (CIRM), the Strategies for Engineered Negligible Senescence (SENS) Research Foundation, UK Cell Therapy Catapult, NIH Centre for Regenerative Medicine, the New York Stem Cell Foundation (NYSCF), ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche and Oxford BioMedica (UK) LCell Consortium (CTSCC) as funding and events partners, without whom the consortium and the benefits it will bring to stem cell translation would be constrained: GE Healthcare, the Center for Commercialization of Regenerative Medicine (CCRM), Sartorius Stedim Biotech (formerly TAP Biosystems), Lonza, the California Institute for Regenerative Medicine (CIRM), the Strategies for Engineered Negligible Senescence (SENS) Research Foundation, UK Cell Therapy Catapult, NIH Centre for Regenerative Medicine, the New York Stem Cell Foundation (NYSCF), ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche and Oxford BioMedica (UK) Lcell translation would be constrained: GE Healthcare, the Center for Commercialization of Regenerative Medicine (CCRM), Sartorius Stedim Biotech (formerly TAP Biosystems), Lonza, the California Institute for Regenerative Medicine (CIRM), the Strategies for Engineered Negligible Senescence (SENS) Research Foundation, UK Cell Therapy Catapult, NIH Centre for Regenerative Medicine, the New York Stem Cell Foundation (NYSCF), ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche and Oxford BioMedica (UK) LCell Therapy Catapult, NIH Centre for Regenerative Medicine, the New York Stem Cell Foundation (NYSCF), ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche and Oxford BioMedica (UK) LCell Foundation (NYSCF), ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche and Oxford BioMedica (UK) Ltd..

Specifically, application of a prefabricated cardiac tissue patch to prevent dilation and to improve pumping efficiency of the infarcted heart offers a promising strategy for making stem cell therapy a clinical reality.